Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2023’, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
- The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects
- The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
A. Menarini Industrie Farmaceutiche Riunite SrlAbbVie Inc
AbelZeta Inc
Adlai Nortye Biopharma Co Ltd
Affimed GmbH
Agenus Inc
Akeso Inc
Amsterdam UMC
location VUmc
Angiocrine Bioscience Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Aurigene Oncology Ltd
Autolus Therapeutics Plc
Auxi Therapeutics Sdn Bhd
Avipep Pty Ltd
AVM Biotechnology LLC
Baylor College of Medicine
BeiGene Ltd
Beijing Boren Hospital
Bio-Path Holdings Inc
Biosyngen Pte Ltd
Bioviz Technologies Pvt Ltd
Bristol-Myers Squibb Co
Carrick Therapeutics Ltd
Catalent Inc
Cellectar Biosciences Inc
Cellectis SA
Celularity Inc
Centre National de la Recherche Scientifique
Checkpoint Therapeutics Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Children's National Research Institute
Children's Research Institute
Chimeric Therapeutics Ltd
Compass Therapeutics Inc
Cornerstone Pharmaceuticals Inc
CStone Pharmaceuticals Co Ltd
Daiichi Sankyo Co Ltd
Dyadic International Inc
Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Genentech USA Inc
Genmab AS
Genor BioPharma Co Ltd
Gibson Oncology LLC
Gilead Sciences Inc
Glenmark Pharmaceuticals Ltd
Guangzhou Sinogen Pharmaceutical Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
Helocyte Biosciences Inc
Hutchison MediPharma Ltd
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immunitas Therapeutics Inc
Incyte Corp
Innovent Biologics Inc
Intellia Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
JSR Life Sciences LLC
Kunming Medical University Hospital 3
Kymera Therapeutics Inc
Les Laboratoires Servier SAS
Luye Pharma Group Ltd
MacroGenics Inc
Marker Therapeutics Inc
MediSix Therapeutics Pte Ltd
MedPacto Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
Mirati Therapeutics Inc
Mundipharma International Ltd
Nanchang University Affiliated Hospital One
Nantes University Hospital
National Cancer Institute US
NewBio Therapeutics Inc
Novartis AG
NuCana Plc
Ono Pharmaceutical Co Ltd
Paul-Ehrlich-Institut
Pfizer Inc
PhorMed Inc
PlantForm Corp
Protheragen Inc
RAPT Therapeutics Inc
Regeneron Pharmaceuticals Inc
Rizen (Suzhou) Biosciences Co Ltd
San Raffaele Scientific Institute
Sanofi
Seagen Inc
SELLAS Life Sciences Group Inc
Shanghai Cell Therapy Group Co
Shanghai First Song Therapeutics Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Stemline Therapeutics Inc
Suzhou Everhealth Biomedical Co Ltd
Syndax Pharmaceuticals Inc
Tacitus Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Tessa Therapeutics Ltd
Tubulis GmbH
Tyme Inc
UNC Lineberger Comprehensive Cancer Center
University Medical Center Utrecht
Vanda Pharmaceuticals Inc
Vincerx Pharma Inc
Viracta Therapeutics Inc
Waterstone Hanxbio Pty Ltd
West Lake Biomedical Technology (Hangzhou) Co Ltd
Wuhan Bio-Raid Biotechnology Co Ltd
Xencor Inc
Zhejiang Borui Biopharmaceutical Co Ltd